REGENXBIO Inc. (NASDAQ:RGNX) is scheduled to post its quarterly earnings results before the market opens on Tuesday, November 7th. Analysts expect REGENXBIO to post earnings of ($0.73) per share for the quarter.

REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.34. The firm had revenue of $6.56 million for the quarter. REGENXBIO had a negative return on equity of 38.74% and a negative net margin of 839.87%. On average, analysts expect REGENXBIO to post $-2.74 EPS for the current fiscal year and $-3.09 EPS for the next fiscal year.

REGENXBIO Inc. (RGNX) opened at 28.75 on Tuesday. The company’s 50-day moving average price is $30.80 and its 200 day moving average price is $30.80. REGENXBIO Inc. has a 52-week low of $15.40 and a 52-week high of $36.10. The firm’s market capitalization is $888.20 million.

In other REGENXBIO news, Director Donald J. Hayden, Jr. sold 20,000 shares of REGENXBIO stock in a transaction dated Wednesday, October 11th. The stock was sold at an average price of $34.95, for a total transaction of $699,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Vittal Vasista sold 3,040 shares of REGENXBIO stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $21.09, for a total value of $64,113.60. Following the transaction, the chief financial officer now owns 103,118 shares in the company, valued at $2,174,758.62. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 210,040 shares of company stock worth $5,874,639. Corporate insiders own 17.00% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was reported by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2017/10/31/regenxbio-inc-rgnx-to-release-earnings-on-tuesday.html.

Several research analysts have weighed in on RGNX shares. Chardan Capital reiterated a “buy” rating and set a $75.00 target price (up from $55.00) on shares of REGENXBIO in a report on Tuesday, September 5th. Zacks Investment Research upgraded REGENXBIO from a “hold” rating to a “strong-buy” rating and set a $38.00 target price on the stock in a report on Wednesday, October 18th. Bank of America Corporation reiterated a “buy” rating and set a $38.00 target price (up from $33.00) on shares of REGENXBIO in a report on Monday, October 9th. Raymond James Financial, Inc. started coverage on REGENXBIO in a report on Thursday, October 12th. They set an “outperform” rating and a $39.00 target price on the stock. Finally, Evercore ISI started coverage on REGENXBIO in a report on Wednesday, August 16th. They set an “outperform” rating and a $25.00 target price on the stock. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $40.00.

About REGENXBIO

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Earnings History for REGENXBIO (NASDAQ:RGNX)

Receive News & Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.